

Long-Term Outcomes of Selective Bladder Preservation Invasive Bladder Cancer: The MGH Experience

European Urology

61, 705-711

DOI: [10.1016/j.eururo.2011.11.010](https://doi.org/10.1016/j.eururo.2011.11.010)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Old Drugs, New Purpose – Bladder Cancer Turning a Corner. <i>New England Journal of Medicine</i> , 2012, 366, 1540-1541.	13.9	7
2	Chemoradiation superior in muscle-invasive bladder cancer. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 374-375.	12.5	6
3	Complications and Long-Term Results of Salvage Cystectomy After Failed Bladder Sparing Therapy for Muscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2012, 187, 463-468.	0.2	95
4	Long-term Results of Two Prospective Bladder-sparing Trimodality Approaches for Invasive Bladder Cancer: Neoadjuvant Chemotherapy and Concurrent Radio-chemotherapy. <i>Urology</i> , 2012, 80, 1056-1062.	0.5	57
5	Expression of TIP60 (tata-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer. <i>BJU International</i> , 2012, 110, E1228-36.	1.3	92
6	Impact of Age and Comorbidity on Treatment and Outcomes in Elderly Cancer Patients. <i>Seminars in Radiation Oncology</i> , 2012, 22, 265-271.	1.0	80
8	Update on the management of invasive bladder cancer 2012. <i>Cancer Management and Research</i> , 2012, 4, 177.	0.9	3
10	Selective bladder preservation with curative intent for muscle-invasive bladder cancer: A contemporary review. <i>International Journal of Urology</i> , 2012, 19, 388-401.	0.5	58
11	Multimodality Treatment Versus Radical Cystectomy: Bladder Sparing at Cost of Life?. <i>European Urology</i> , 2012, 61, 712-713.	0.9	4
13	Re: Jason A. Efstathiou, Daphna Y. Spiegel, William U. Shipley, et al. Long-Term Outcomes of Selective Bladder Preservation by Combined-Modality Therapy for Invasive Bladder Cancer: The MGH Experience. <i>Eur Urol</i> 2012;61:705-11. <i>European Urology</i> , 2012, 62, e41.	0.9	1
14	Reply to Neeraj Kumar Goyal, Manish Garg, and Apul Goel's Letter to the Editor re: Re: Jason A. Efstathiou, Daphna Y. Spiegel, William U. Shipley, et al. Long-Term Outcomes of Selective Bladder Preservation by Combined-Modality Therapy for Invasive Bladder Cancer: The MGH Experience. <i>Eur Urol</i> 2012;61:705-11. <i>European Urology</i> , 2012, 62, e42.	0.9	1
15	Cancer treatment and survivorship statistics, 2012. <i>Ca-A Cancer Journal for Clinicians</i> , 2012, 62, 220-241.	157.7	2,467
16	Target expression of Staphylococcus enterotoxin A from an oncolytic adenovirus suppresses mouse bladder tumor growth and recruits CD3+ T cell. <i>Tumor Biology</i> , 2013, 34, 2863-2869.	0.8	6
17	High FOXM1 expression was associated with bladder carcinogenesis. <i>Tumor Biology</i> , 2013, 34, 1131-1138.	0.8	26
18	Knockdown BMI1 expression inhibits proliferation and invasion in human bladder cancer T24 cells. <i>Molecular and Cellular Biochemistry</i> , 2013, 382, 283-291.	1.4	22
19	Trimodality Therapy for Bladder Conservation in Treatment of Invasive Bladder Cancer. <i>Current Urology Reports</i> , 2013, 14, 109-115.	1.0	14
21	Female sex is an independent risk factor for reduced overall survival in bladder cancer patients treated by transurethral resection and radio- or radiochemotherapy. <i>World Journal of Urology</i> , 2013, 31, 1023-1028.	1.2	26
22	Radical Cystectomy versus Bladder-Preserving Therapy for Muscle-Invasive Urothelial Carcinoma: Examining Confounding and Misclassification Bias in Cancer Observational Comparative Effectiveness Research. <i>Value in Health</i> , 2013, 16, 610-618.	0.1	56

#	ARTICLE	IF	CITATIONS
23	Use of Potentially Curative Therapies for Muscle-invasive Bladder Cancer in the United States: Results from the National Cancer Data Base. <i>European Urology</i> , 2013, 63, 823-829.	0.9	204
24	Trimodality treatment in the conservative management of infiltrating bladder cancer: A critical review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 86, 176-190.	2.0	15
26	ICUD-EAU International Consultation on Bladder Cancer 2012: Radical Cystectomy and Bladder Preservation for Muscle-Invasive Urothelial Carcinoma of the Bladder. <i>European Urology</i> , 2013, 63, 45-57.	0.9	361
27	Re: Radiotherapy with or without Chemotherapy in Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2013, 63, 181-182.	0.9	4
28	Targeting Folate Receptors to Treat Invasive Urinary Bladder Cancer. <i>Cancer Research</i> , 2013, 73, 875-884.	0.4	52
29	Re: Radiotherapy With or Without Chemotherapy in Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2013, 63, 580-581.	0.9	4
30	Adaptive plan selection vs. re-optimisation in radiotherapy for bladder cancer: A dose accumulation comparison. <i>Radiotherapy and Oncology</i> , 2013, 109, 457-462.	0.3	68
31	Nomograms Predicting Response to Therapy and Outcomes After Bladder-Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 311-316.	0.4	32
32	Randomized Noninferiority Trial of Reduced High-Dose Volume Versus Standard Volume Radiation Therapy for Muscle-Invasive Bladder Cancer: Results of the BC2001 Trial (CRUK/01/004). <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 261-269.	0.4	115
33	Recent advances in the diagnosis and treatment of bladder cancer. <i>BMC Medicine</i> , 2013, 11, 13.	2.3	142
34	Bladder preservation in the treatment of muscle-invasive bladder cancer (<sc>MIBC</sc>): a review of the literature and a practical approach to therapy. <i>BJU International</i> , 2013, 112, 13-25.	1.3	67
35	Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. <i>Lancet Oncology</i> , The, 2013, 14, 863-872.	5.1	129
36	Primary Bladder Preservation Treatment for Urothelial Bladder Cancer. <i>Cancer Control</i> , 2013, 20, 188-199.	0.7	26
37	Radio-chemotherapy for bladder cancer: Contribution of chemotherapy on local control. <i>World Journal of Radiology</i> , 2013, 5, 267.	0.5	11
38	New therapeutic targets in the management of urothelial carcinoma of the bladder. <i>Research and Reports in Urology</i> , 2013, 5, 53.	0.6	5
39	Transurethral resection and degeneration of bladder tumour. <i>Canadian Urological Association Journal</i> , 2013, 7, 812.	0.3	2
40	Transurethral resection, neoadjuvant chemotherapy and accelerated hyperfractionated radiotherapy – concomitant boost, with or without concurrent cisplatin, for patients with invasive bladder cancer – clinical outcome. <i>Wspolczesna Onkologia</i> , 2013, 3, 302-306.	0.7	3
41	Metastasis After Primary Treatment – Peri-Operative and Bladder-Preservation Therapy in Muscle Invasive Diseases. , 2013, , .		0

#	ARTICLE	IF	CITATIONS
42	Current Evidence for the Treatment of Bladder Cancer. <i>The Ewha Medical Journal</i> , 2014, 37, 1.	0.1	1
43	Muscle-invasive bladder cancer: evaluating treatment and survival in the national cancer database. <i>BJU International</i> , 2014, 114, 719-726.	1.3	132
44	Trimodality bladder-sparing approach versus radical cystectomy for invasive bladder cancer. <i>Journal of Radiotherapy in Practice</i> , 2014, 13, 428-437.	0.2	8
45	Strategies to improve quality of life in bladder cancer patients. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 537-544.	0.7	3
46	Prospective Phase II Study of Image-guided Local Boost Using a Real-time Tumor-tracking Radiotherapy (TRT) System for Locally Advanced Bladder Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 28-35.	0.6	6
47	Selective organ preservation for the treatment of muscle-invasive transitional cell carcinoma of the bladder: a review of current and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1429-1443.	1.1	1
48	Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer. <i>Annals of Oncology</i> , 2014, 25, 877-883.	0.6	41
49	Long-Term Outcomes in Patients With Muscle-Invasive Bladder Cancer After Selective Bladder-Preserving Combined-Modality Therapy: A Pooled Analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 0233. <i>Journal of Clinical Oncology</i> , 2014, 32, 3801-3809.	0.8	353
50	Novel neoadjuvant therapy paradigms for bladder cancer: Results from the National Cancer Center Institute Forum. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1108-1115.	0.8	24
52	Trimodality Therapy for Bladder Preservation in the Elderly Population with Invasive Bladder Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 206.	1.3	17
53	Patterns of Practice in the Radiation Therapy for Bladder Cancer: Survey of the Japanese Radiation Oncology Study Group (JROSG). <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 1109-1115.	0.6	9
54	Expression of ribonucleoside reductase subunit M1, but not excision repair cross-complementation group 1, is predictive in muscle-invasive bladder cancer treated with chemotherapy and radiation. <i>Molecular and Clinical Oncology</i> , 2014, 2, 479-487.	0.4	10
55	Bladder preservation with brachytherapy compared to cystectomy for T1-T3 muscle-invasive bladder cancer: a systematic review. <i>Journal of Contemporary Brachytherapy</i> , 2014, 2, 191-199.	0.4	13
56	Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival. <i>Radiation Oncology</i> , 2014, 9, 213.	1.2	15
57	Clinical Pathologic Stage Discrepancy in Bladder Cancer Patients Treated With Radical Cystectomy: Results From the National Cancer Data Base. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 1048-1056.	0.4	71
58	The outcome of a multi-centre feasibility study of online adaptive radiotherapy for muscle-invasive bladder cancer TROG 10.01 BOLART. <i>Radiotherapy and Oncology</i> , 2014, 111, 316-320.	0.3	42
59	Preservación vesical electiva en tumor vesical músculo invasivo. <i>Actas Urológicas Españolas</i> , 2014, 38, 7-13.	0.3	2
60	Elective bladder-sparing treatment for muscle invasive bladder cancer. <i>Actas Urológicas Españolas (English Edition)</i> , 2014, 38, 7-13.	0.2	1

#	ARTICLE	IF	CITATIONS
61	Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2014, 66, 120-137.	0.9	277
62	Organ preservation for muscle-invasive bladder cancer by preoperative intra-arterial chemotherapy and transurethral resection. <i>Medical Oncology</i> , 2014, 31, 912.	1.2	14
63	Long-term Outcomes in Treatment of Invasive Bladder Cancer With Concomitant Boost and Accelerated Hyperfractionated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 562-569.	0.4	3
64	CAV-1 contributes to bladder cancer progression by inducing epithelial-to-mesenchymal transition. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 855-863.	0.8	45
65	Multimodal management of muscle-invasive bladder cancer. <i>Current Problems in Cancer</i> , 2014, 38, 80-108.	1.0	76
66	Significance of ERBB2 Overexpression in Therapeutic Resistance and Cancer-Specific Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Selective Bladder-Sparing Approach. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 303-311.	0.4	34
67	Image guided radiation therapy for bladder cancer: Assessment of bladder motion using implanted fiducial markers. <i>Practical Radiation Oncology</i> , 2014, 4, 108-115.	1.1	14
68	Role of Maximal Endoscopic Resection Before Cystectomy for Invasive Urothelial Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 287-291.	0.9	20
69	Treating octogenarians with muscle-invasive bladder cancer: Preoperative opportunities for increasing the benefits of surgical intervention. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 37.e13-37.e16.	0.8	5
70	Reply. <i>Urology</i> , 2014, 83, 950.	0.5	0
71	Hypofractionated Intensity Modulated Radiation Therapy in Combined Modality Treatment for Bladder Preservation in Elderly Patients With Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 326-331.	0.4	72
72	Outcomes of radical cystectomy and bladder preservation treatment for muscle-invasive urothelial carcinoma of the bladder. <i>Asian Journal of Surgery</i> , 2014, 37, 184-189.	0.2	7
73	Cancer treatment and survivorship statistics, 2014. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 252-271.	157.7	2,474
74	T2 Muscle-Invasive Bladder Cancer. <i>Seminars in Oncology</i> , 2014, 41, e11-e18.	0.8	0
75	Altholactone induces reactive oxygen species-mediated apoptosis in bladder cancer T24 cells through mitochondrial dysfunction, MAPK-p38 activation and Akt suppression. <i>Oncology Reports</i> , 2014, 31, 2769-2775.	1.2	19
77	PD31-13 PERI-OPERATIVE MORTALITY AND LONG-TERM SURVIVAL AFTER PARTIAL VERSUS RADICAL CYSTECTOMY FOR MUSCLE INVASIVE BLADDER CANCER. <i>Journal of Urology</i> , 2015, 193, .	0.2	0
78	Management of cancer of the bladder. , 0, , 304-313.		0
79	Immunotherapy and Radiation – A New Combined Treatment Approach for Bladder Cancer?. <i>Bladder Cancer</i> , 2015, 1, 15-27.	0.2	19

#	ARTICLE	IF	CITATIONS
80	Continuous chemoradiation following complete response to neo-adjuvant chemotherapy provides improved outcomes in muscle invasive urothelial carcinoma. <i>Journal of Solid Tumors</i> , 2015, 5, .	0.1	0
81	Outcomes of Radical Cystectomy in Potential Candidates for Bladder Preservation Therapy. <i>Urology</i> , 2015, 85, 869-875.	0.5	18
82	Diagnosis of Bladder Carcinoma. <i>Surgical Pathology Clinics</i> , 2015, 8, 677-685.	0.7	17
83	Repression of engrailed 2 inhibits the proliferation and invasion of human bladder cancer in vitro and in vivo. <i>Oncology Reports</i> , 2015, 33, 2319-2330.	1.2	11
84	Bladder Preservation Strategies. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 289-300.	0.9	10
85	Organ Preservation "Will Data Translate into Reality for Bladder Cancer Patients?. <i>Clinical Oncology</i> , 2015, 27, 133-135.	0.6	3
86	Novel Bladder Preservation Therapy with Osaka Medical College Regimen. <i>Journal of Urology</i> , 2015, 193, 443-450.	0.2	13
87	Quality of life in patients with non-muscle-invasive bladder cancer. <i>Nature Reviews Urology</i> , 2015, 12, 186-188.	1.9	10
88	Evaluation of delivered dose for a clinical daily adaptive plan selection strategy for bladder cancer radiotherapy. <i>Radiotherapy and Oncology</i> , 2015, 116, 51-56.	0.3	39
89	High Ki-67 Expression Predicts Favorable Survival in Muscle-Invasive Bladder Cancer Patients Treated With Chemoradiation-Based Bladder-Sparing Protocol. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e243-e251.	0.9	22
90	Re: Long-Term Outcomes in Patients with Muscle-Invasive Bladder Cancer After Selective Bladder-Preserving Combined-Modality Therapy: A Pooled Analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 0233. <i>European Urology</i> , 2015, 68, 165-166.	0.9	2
91	Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder. <i>British Journal of Cancer</i> , 2015, 112, 1626-1635.	2.9	27
92	Trimodality Therapy in Bladder Cancer. <i>Urologic Clinics of North America</i> , 2015, 42, 169-180.	0.8	36
93	Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 53-64.	0.8	11
96	A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC). <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 105-115.	2.0	65
97	Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 387-396.	2.0	100
98	Intra-Arterial Chemotherapy for Muscle-Invasive Bladder Cancer Following Transurethral Resection. <i>Urologia Internationalis</i> , 2015, 94, 406-411.	0.6	9
99	Radical cystectomy vs. chemoradiation in T2-4aNOMO bladder cancer: A case-control study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 19.e1-19.e5.	0.8	40

#	ARTICLE	IF	CITATIONS
100	Transurethral Bladder Tumor Resection Can Cause Seeding of Cancer Cells into the Bloodstream. <i>Journal of Urology</i> , 2015, 193, 53-57.	0.2	69
101	Current clinical practice guidelines on chemotherapy and radiotherapy for the treatment of non-metastatic muscle-invasive urothelial cancer: A systematic review and critical evaluation by the Hellenic Genito-Urinary Cancer Group (HGUCG). <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 36-49.	2.0	18
102	Treatment of Muscle-Invasive Bladder Cancer in Older Patients. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e228-e233.	1.8	4
103	A biological modeling based comparison of two strategies for adaptive radiotherapy of urinary bladder cancer. <i>Acta Oncologica</i> , 2016, 55, 1009-1015.	0.8	5
104	New Updates Pertaining to Drug Delivery of Local Anesthetics in Particular Bupivacaine Using Lipid Nanoparticles. <i>Nanoscale Research Letters</i> , 2016, 11, 307.	3.1	54
106	Re: Radical Cystectomy vs. Chemoradiation in T2-4aNOMO Bladder Cancer: A Case-control Study. <i>European Urology</i> , 2016, 69, 757-758.	0.9	0
107	Diversity in treatment modalities of Stage II/III urothelial cancer in Japan: sub-analysis of the multi-institutional national database of the Japanese Urological Association. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 468-474.	0.6	4
108	A 10-Item Checklist Improves Reporting of Critical Procedural Elements during Transurethral Resection of Bladder Tumor. <i>Journal of Urology</i> , 2016, 196, 1014-1020.	0.2	41
109	Radical Cystectomy and the Multidisciplinary Management of Muscle-Invasive Bladder Cancer. <i>JAMA Oncology</i> , 2016, 2, 855.	3.4	12
110	Chemoradiation for organ preservation in the treatment of muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 271-278.	0.8	8
111	Hyperthermia and radiotherapy in bladder cancer. <i>International Journal of Hyperthermia</i> , 2016, 32, 398-406.	1.1	15
112	Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 1028-1036.	0.4	122
114	Adjuvant Chemotherapy Is More Suitable Than Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer Patients Treated With Radical Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 614-616.	0.4	6
115	Concurrent chemoradiotherapy in elderly patients with muscle-invasive bladder cancer: A single-center experience. <i>Journal of Cancer Research and Practice</i> , 2016, 3, 73-76.	0.2	3
116	Cancer treatment and survivorship statistics, 2016. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 271-289.	157.7	4,123
117	Outcome of patients with nonmetastatic muscle-invasive bladder cancer not undergoing cystectomy after treatment with noncisplatin-based chemotherapy and/or radiotherapy: a retrospective analysis. <i>Cancer Medicine</i> , 2016, 5, 1098-1107.	1.3	6
118	Bladder Preservation for Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 151-163.	0.2	25
119	The feasibility and safety of cryoablation as an adjuvant therapy with transurethral resection of bladder tumor: A pilot study. <i>Cryobiology</i> , 2016, 73, 257-260.	0.3	12

#	ARTICLE	IF	CITATIONS
121	The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 381-394.	0.2	15
122	Bladder cancer. <i>Lancet</i> , The, 2016, 388, 2796-2810.	6.3	1,031
123	Radiation therapy for urological cancers. <i>Journal of Clinical Urology</i> , 2016, 9, 142-150.	0.1	0
124	Clinical results of conformal versus intensity-modulated radiotherapy using a focal simultaneous boost for muscle-invasive bladder cancer in elderly or medically unfit patients. <i>Radiation Oncology</i> , 2016, 11, 45.	1.2	29
125	Bladder Preservation Therapy: A Review of the Literature and Future Directions. <i>Urology</i> , 2016, 96, 54-61.	0.5	16
126	Propensity score and doubly robust methods for estimating the effect of treatment on censored cost. <i>Statistics in Medicine</i> , 2016, 35, 1985-1999.	0.8	14
127	Is hyperthermia combined with radiotherapy adequate in elderly patients with muscle-invasive bladder cancers? Thermo-radiobiological implications from an audit of initial results. <i>International Journal of Hyperthermia</i> , 2016, 32, 390-397.	1.1	8
128	A review of the use of fiducial markers for image-guided bladder radiotherapy. <i>Acta Oncologica</i> , 2016, 55, 533-538.	0.8	12
129	Surgical bladder-preserving techniques in the management of muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 262-270.	0.8	8
130	Muscle-invasive bladder cancer treated with TURB followed by concomitant boost with small reduction of radiotherapy field with or without of chemotherapy. <i>Reports of Practical Oncology and Radiotherapy</i> , 2016, 21, 31-36.	0.3	5
131	Clinical Outcomes With Dose-Escalated Adaptive Radiation Therapy for Urinary Bladder Cancer: A Prospective Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 60-66.	0.4	30
133	Significance of second transurethral resection on patient outcomes in muscle-invasive bladder cancer patients treated with bladder-preserving multimodal therapy. <i>World Journal of Urology</i> , 2016, 34, 847-851.	1.2	17
134	Underutilization of Radical Cystectomy Among Patients Diagnosed with Clinical Stage T2 Muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2017, 3, 258-264.	1.6	51
135	Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy. <i>European Urology</i> , 2017, 72, 54-60.	0.9	64
136	Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. <i>European Urology</i> , 2017, 71, 952-960.	0.9	253
137	Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuited for Radical Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 115-122.	0.4	48
139	Trimodal Therapy is Inferior to Radical Cystectomy for Muscle-invasive Bladder Cancer using Population-level Data: Is There Evidence in the (Lack of) Details?. <i>European Urology</i> , 2017, 72, 488-489.	0.9	6
140	Incidental Dose to Pelvic Nodes in Bladder-Only Radiotherapy: Is It Clinically Relevant?. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 382-387.	0.8	9

#	ARTICLE	IF	CITATIONS
141	A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524). <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 995-1001.	0.4	45
142	A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 689-696.	0.8	9
143	Radical Cystectomy Compared to Combined Modality Treatment for Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 1002-1020.	0.4	93
144	Should we care more about <scp>SPARE</scp>?. <i>BJU International</i> , 2017, 120, 605-606.	1.3	1
145	Bladder Preservation Therapies in Bladder Cancer. , 2017, , 85-101.		0
146	Comparative analysis between radical cystectomy and trimodality therapy for clinical stage II bladder cancer – Experience from a tertiary referral center. <i>Urological Science</i> , 2017, , .	0.2	0
147	The Efficacy of Trimodal Chemoradiotherapy with Cisplatin as a Bladder-Preserving Strategy for the Treatment of Muscle-Invasive Bladder Cancer. <i>Urologia Internationalis</i> , 2017, 99, 446-452.	0.6	16
148	Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer. <i>Cancer</i> , 2017, 123, 4337-4345.	2.0	72
149	How Octogenarians with Bladder Cancer Are Treated in a Maximum-Care Hospital: The Real-Life Experience. <i>Urologia Internationalis</i> , 2017, 98, 262-267.	0.6	7
150	Analysis of inter- and intra fractional partial bladder wall movement using implanted fiducial markers. <i>Radiation Oncology</i> , 2017, 12, 44.	1.2	8
151	Long-term single-institute experience with trimodal bladder-preserving therapy with proton beam therapy for muscle-invasive bladder cancer. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 67-73.	0.6	15
152	Tolerability of Concurrent Chemoradiation Therapy With Gemcitabine (GemX), With and Without Prior Neoadjuvant Chemotherapy, in Muscle Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 732-739.	0.4	26
155	A low psoas muscle volume correlates with a longer hospitalization after radical cystectomy. <i>BMC Urology</i> , 2017, 17, 87.	0.6	40
156	Chemoradiotherapy in octogenarians as primary treatment for muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2017, 11, 24.	0.3	8
157	Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. <i>Journal of Clinical Oncology</i> , 2017, 35, 2299-2305.	0.8	241
158	Trimodality therapy in variant urothelial carcinoma: choose wisely. <i>Translational Andrology and Urology</i> , 2017, 6, 322-325.	0.6	3
159	Can bladder preservation therapy come to the center stage?. <i>International Journal of Urology</i> , 2018, 25, 134-140.	0.5	6
162	Lymph node dissection during radical cystectomy following prior radiation therapy: results from the SEER database. <i>International Urology and Nephrology</i> , 2018, 50, 257-262.	0.6	3

#	ARTICLE	IF	CITATIONS
163	Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle-invasive bladder cancer. <i>BJU International</i> , 2018, 121, 745-751.	1.3	37
164	Chloroquine Enhances the Radiosensitivity of Bladder Cancer Cells by Inhibiting Autophagy and Activating Apoptosis. <i>Cellular Physiology and Biochemistry</i> , 2018, 45, 54-66.	1.1	72
165	Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 213-218.	0.9	13
166	Concurrent chemoradiotherapy for bladder cancer: Practice patterns and outcomes in the general population. <i>Radiotherapy and Oncology</i> , 2018, 127, 136-142.	0.3	10
167	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 310-320.	2.3	476
168	Whole Versus Partial Bladder Radiation. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 107-114.	0.6	16
169	Routine bladder cancer treatment dictates divergence from trial-derived regimens: Results of treatment at 44 radiotherapy centers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 9.e19-9.e25.	0.8	1
170	Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. <i>Acta Oncologica</i> , 2018, 57, 491-497.	0.8	22
171	Radiosensitization <i>In Vivo</i> by Histone Deacetylase Inhibition with No Increase in Early Normal Tissue Radiation Toxicity. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 381-392.	1.9	31
172	Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2018, 199, 407-415.	0.2	34
173	Curative radiation therapy for very elderly bladder cancer patients with localized disease. <i>Clinical and Translational Oncology</i> , 2018, 20, 899-905.	1.2	8
175	Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1949-1956.	0.8	110
176	Canadian Urological Association guideline: Muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2018, 13, 230-238.	0.3	51
178	Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer. <i>Lancet Oncology</i> , 2018, 19, e683-e695.	5.1	74
179	A Festschrift in Honor of Edward M. Messing, MD, FACS. <i>Bladder Cancer</i> , 2018, 4, S1-S43.	0.2	0
181	Trimodal therapy for muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1219-1229.	1.1	9
182	The Surveillance for Muscle-Invasive Bladder Cancer (MIBC). , 2018, , 553-597.		1
185	Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer. <i>Current Oncology Reports</i> , 2018, 20, 66.	1.8	7

#	ARTICLE	IF	CITATIONS
186	Muscle-invasive bladder cancer organ-preserving therapy: systematic review and meta-analysis. World Journal of Urology, 2018, 36, 1997-2008.	1.2	30
188	Conservative Management Following Complete Clinical Response to Neoadjuvant Chemotherapy of Muscle Invasive Bladder Cancer: Contemporary Outcomes of a Multi-Institutional Cohort Study. Journal of Urology, 2018, 200, 1005-1013.	0.2	47
190	Treatment of Urothelial Cancer in Elderly Patients: Focus on Immune Checkpoint Inhibitors. Drugs and Aging, 2018, 35, 409-421.	1.3	6
191	Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical) Tj ETQq1 1 0.784314 rgBT /Over 0.9 372	0.9	6
192	Evaluating the Current Place of Radiotherapy as Treatment Option for Patients With Muscle Invasive Bladder Cancer in Belgium. Clinical Genitourinary Cancer, 2018, 16, e1159-e1169.	0.9	6
193	Comparison of Outcomes in Patients With Muscle-invasive Bladder Cancer Treated With Radical Cystectomy Versus Bladder Preservation. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 36-41.	0.6	41
194	Chemoradiation Vs Radical Cystectomy for Muscle-invasive Bladder Cancer: A Propensity Score-weighted Comparative Analysis Using the National Cancer Database. Urology, 2019, 133, 164-174.	0.5	15
195	Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2). Oncologist, 2019, 24, e1341-e1350.	1.9	28
196	Review of hypo-fractionated radiotherapy for localized muscle invasive bladder cancer. Critical Reviews in Oncology/Hematology, 2019, 142, 76-85.	2.0	9
197	Multimodality Treatment for Bladder Conservation. , 2019, , 373-382.		0
199	Treatment Options and Outcomes in Nonmetastatic Muscle Invasive Bladder Cancer. Trends in Cancer, 2019, 5, 426-439.	3.8	52
200	Adaptive Radiotherapy for Carcinoma of the Urinary Bladder: Long-term Outcomes With Dose Escalation. Clinical Oncology, 2019, 31, 646-652.	0.6	18
201	A multi-institutional study of bladder-preserving therapy for stage II-IV bladder cancer: A Korean Radiation Oncology Group Study (KROG 14-16). PLoS ONE, 2019, 14, e0209998.	1.1	1
202	Multimodality Therapy. , 2019, , 115-122.		0
203	Immunohistochemistry in the workup of bladder biopsies: Frequency, variation and utility of use at an academic center. Annals of Diagnostic Pathology, 2019, 41, 124-128.	0.6	4
204	Selective tetramodal bladderâ€preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscleâ€invasive bladder cancer: oncological and functional outcomes of 107 patients. BJU International, 2019, 124, 242-250.	1.3	35
206	MicroRNA Biomarkers for Patients With Muscle-Invasive Bladder Cancer Undergoing Selective Bladder-Sparing Trimodality Treatment. International Journal of Radiation Oncology Biology Physics, 2019, 104, 197-206.	0.4	13
207	Circular RNA CEP128 promotes bladder cancer progression by regulating Mirâ€145â€5p/Myd88</i> via MAPK signaling pathway. International Journal of Cancer, 2019, 145, 2170-2181.	2.3	50

#	ARTICLE	IF	CITATIONS
208	Molecular Characterization of Neuroendocrine-like Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3908-3920.	3.2	71
209	Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712â€”A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 44-51.	0.8	83
210	Prognosis of early stage small cell bladder cancer is not always dismal. <i>ESMO Open</i> , 2019, 4, e000559.	2.0	4
211	Editorial comment: understanding the cost of bladder preservation in muscle invasive bladder cancerâ€”an evaluation of radical cystectomy versus trimodal therapy costs. <i>Translational Andrology and Urology</i> , 2019, 8, S463-S465.	0.6	0
212	The challenge of matching assays to biology in DNA damage response biomarkers for response to radiotherapy in bladder cancer. <i>Translational Andrology and Urology</i> , 2019, 8, S514-S516.	0.6	2
213	Trimodality therapy for bladder cancer. <i>Current Opinion in Urology</i> , 2019, 29, 210-215.	0.9	30
214	Nuclear Factor-Î² Overexpression is Correlated with Poor Outcomes after Multimodality Bladder-Preserving Therapy in Patients with Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 1954.	1.0	8
215	Imaging in Localized Bladder Cancer: Can Current Diagnostic Modalities Provide Accurate Local Tumor Staging?. <i>Current Urology Reports</i> , 2019, 20, 82.	1.0	13
216	Prognostic value of nutritional indices and body composition parameters including sarcopenia in patients treated with radiotherapy for urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 372-379.	0.8	24
217	Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 38-45.	0.9	29
218	Oncofertility in urologic oncology: Fertility preservation for women undergoing cancer treatment. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 14-22.	0.8	1
219	Quality Indicators for Bladder Cancer Services: A Collaborative Review. <i>European Urology</i> , 2020, 78, 43-59.	0.9	34
220	Carcinoma of the Bladder. , 2020, , 1382-1400.e4.		2
221	Screening logs from a pilot randomized controlled trial of radical cystectomy versus chemoradiation therapy for muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 4.e1-4.e6.	0.8	3
222	Clinical Outcomes of Patients With Histologic Variants of Urothelial Carcinoma Treated With Selective Tetramodal Bladder-preservation Therapy Incorporating Consolidative Partial Cystectomy. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 268-273.e2.	0.9	4
223	Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis. <i>World Journal of Urology</i> , 2021, 39, 1757-1768.	1.2	20
224	Emerging Roles of Urine-Based Tumor DNA Analysis in Bladder Cancer Management. <i>JCO Precision Oncology</i> , 2020, 4, 806-817.	1.5	7
225	Will chemoradiation-based bladder-sparing therapy become a standard of care for muscle-invasive bladder cancer?. <i>Translational Andrology and Urology</i> , 2020, 9, 981-982.	0.6	0

#	ARTICLE	IF	CITATIONS
226	FROGG patterns of practice survey and consensus recommendations on radiation therapy for MIBC. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 882-893.	0.9	4
227	Bladder preservation therapy for muscle invasive bladder cancer: the past, present and future. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1097-1107.	0.6	19
229	Trimodal Therapy vs. Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 564779.	1.3	11
230	Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2020, 14, 404-410.	0.3	3
231	Androgen receptor in bladder cancer: A promising therapeutic target. <i>Asian Journal of Urology</i> , 2020, 7, 284-290.	0.5	25
232	Outcomes and Profiles of Older Patients Receiving Definitive Radiation Therapy for Muscle-Invasive Bladder Cancer at a Tertiary Medical Center. <i>Practical Radiation Oncology</i> , 2020, 10, e378-e387.	1.1	1
233	Current Management of Localized Muscle-Invasive Bladder Cancer: A Consensus Guideline from the Genitourinary Medical Oncologists of Canada. <i>Bladder Cancer</i> , 2020, 6, 363-392.	0.2	1
235	Management of bladder cancer in older patients: Position paper of a SIOG Task Force. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1043-1053.	0.5	46
236	Management of Muscle-invasive Bladder Cancer in the 2020s: Challenges and Perspectives. <i>European Urology Focus</i> , 2020, 6, 632-638.	1.6	30
237	Comparative effectiveness of radical cystectomy and radiotherapy without chemotherapy in frail patients with bladder cancer. <i>Scandinavian Journal of Urology</i> , 2020, 54, 52-57.	0.6	4
238	Feasibility and outcomes of selective tetramodal bladder preservation therapy in elderly patients with muscle-invasive bladder cancer. <i>International Journal of Urology</i> , 2020, 27, 236-243.	0.5	7
239	Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions. <i>Current Oncology Reports</i> , 2020, 22, 14.	1.8	16
240	The updated outcomes of bladder-preserving trimodal therapy using a real-time tumor-tracking radiotherapy system for patients with muscle-invasive bladder cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 609-616.	0.6	3
242	Failing to Close the Gap Between Evidence and Clinical Practice in Radical Bladder Cancer Radiotherapy. <i>Clinical Oncology</i> , 2021, 33, 46-49.	0.6	6
243	Association between low prostate-specific antigen levels and greater disease progression in high-grade locally-advanced prostate cancer. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 483-491.	0.8	4
244	Current Landscape and Future Directions on Bladder Sparing Approaches to Muscle-Invasive Bladder Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 3.	1.3	3
245	Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 953-963.	0.4	6
246	Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response. <i>World Journal of Urology</i> , 2021, 39, 1331-1343.	1.2	34

#	ARTICLE	IF	CITATIONS
247	Managing Urothelial Recurrences after Chemoradiation Therapy. , 2021, , 281-287.		0
248	Population-based outcome of muscle-invasive bladder cancer following radical cystectomy: who can benefit from adjuvant chemotherapy?. Translational Andrology and Urology, 2021, 10, 356-373.	0.6	2
249	Bladder Cancer Tissue-Based Biomarkers. Societ�� Internationale D'urologie Journal, 2021, 2, 53-71.	0.2	0
250	Trimodal Therapy. , 2021, , 257-280.		0
251	Complete Transurethral Resection before Radical Cystectomy May Improve Oncological Outcomes. Urologia Internationalis, 2022, 106, 122-129.	0.6	3
252	Endoclips as novel fiducial markers in trimodality bladder-preserving therapy of muscle-invasive bladder carcinoma: feasibility and patient outcomes. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2021, 47, 93-99.	0.7	3
253	Neoadjuvant Chemotherapy��Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study. Cancer Research and Treatment, 2021, 53, 1156-1165.	1.3	10
254	Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. Lancet Oncology, The, 2021, 22, 246-255.	5.1	73
255	Surgical challenges and considerations in Tri-modal therapy for muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 442-450.	0.8	7
256	Imaging and Management of Bladder Cancer. Cancers, 2021, 13, 1396.	1.7	30
257	Bladder preservation therapy in combination with atezolizumab and radiation therapy for invasive bladder cancer (BPT-ART) �� A study protocol for an open-label, phase II, multicenter study. Contemporary Clinical Trials Communications, 2021, 21, 100724.	0.5	3
258	The Diagnosis and Treatment of Patients with Bladder Carcinoma. Deutsches Ärztblatt International, 2020, 118, .	0.6	4
259	Impact of preoperative sarcopenia and myosteatosis on prognosis after radical cystectomy in patients with bladder cancer. International Journal of Urology, 2021, 28, 757-762.	0.5	12
261	Overcoming the Chasm Between Evidence and Routine Practice for Bladder Cancer; Just a Quixotic Notion?. Clinical Oncology, 2021, 33, e274-e284.	0.6	2
262	Characterization and management of NMIBC recurrences after TMT: a matched cohort analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 835.e1-835.e7.	0.8	3
263	A phase II study of neoadjuvant chemotherapy followed by organ preservation in patients with muscle-invasive bladder cancer. Asian Journal of Urology, 2021, , .	0.5	0
264	Contemporary radiotherapy: present and future. Lancet, The, 2021, 398, 171-184.	6.3	94
265	Vinorelbine in bladder-preserving multimodality treatment for muscle-invasive bladder cancer��a valid option for cisplatin-unfit patients?. Strahlentherapie Und Onkologie, 2021, , 1.	1.0	1

#	ARTICLE	IF	CITATIONS
266	Survival Impact of Current-Smoking-Related COPD or COPD with Acute Exacerbation on Bladder Preservation through Concurrent Chemoradiotherapy for Muscle-Invasive Bladder Urothelial Carcinoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 958.	1.1	2
268	Myosteatosis as a novel prognostic biomarker after radical cystectomy for bladder cancer. <i>Scientific Reports</i> , 2020, 10, 22146.	1.6	9
269	Desethylamiodaroneâ€”A metabolite of amiodaroneâ€”Induces apoptosis on T24 human bladder cancer cells via multiple pathways. <i>PLoS ONE</i> , 2017, 12, e0189470.	1.1	17
270	Bladder preservation in the treatment of muscle-invasive bladder cancer. <i>Bladder</i> , 2014, 1, 5.	0.6	2
271	Increased utilization of external beam radiotherapy relative to cystectomy for localized, muscle-invasive bladder cancer: a SEER analysis. <i>Bladder</i> , 2018, 5, e34.	0.6	2
272	Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer. <i>Translational Andrology and Urology</i> , 2020, 9, 2920-2937.	0.6	14
273	Radiotherapy for Muscle-invasive Bladder Cancer in Very Elderly Patients. <i>Anticancer Research</i> , 2016, 36, 4763-4770.	0.5	11
274	Concurrent Chemotherapy Improves the Overall Survival of Patients Irradiated for Locally Recurrent Bladder Cancer. <i>Anticancer Research</i> , 2017, 37, 1485-1488.	0.5	6
275	Bladder-sparing treatment in MIBC: where do we stand?. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019, 71, 101-112.	3.9	17
276	Review of Experimental Studies to Improve Radiotherapy Response in Bladder Cancer: Comments and Perspectives. <i>Cancers</i> , 2021, 13, 87.	1.7	10
277	Concurrent chemoradiotherapy improves survival outcome in muscle-invasive bladder cancer. <i>Radiation Oncology Journal</i> , 2015, 33, 294.	0.7	16
278	Urinary adverse effects of pelvic radiotherapy. <i>Translational Andrology and Urology</i> , 2014, 3, 186-95.	0.6	34
279	Where are we with bladder preservation for muscle-invasive bladder cancer in 2017?. <i>Indian Journal of Urology</i> , 2017, 33, 111.	0.2	7
280	Ureteroscopic treatment of patients with small, painful, non-obstructing renal stones: the small stone syndrome. <i>Clinical Nephrology</i> , 2013, 79, 45-49.	0.4	10
281	Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. <i>Canadian Urological Association Journal</i> , 2016, 10, 46.	0.3	55
282	Comparison of Radical Cystectomy and Chemoradiotherapy in Patients with Locally Advanced Bladder Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 6519-6524.	0.5	9
283	A Multidisciplinary Approach in Muscle-Invasive Disease: Novel Chemotherapy Combinations and Targets in Chemoradiation. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 200-206.	1.8	0
284	Rola teleradioterapii w inwazyjnym raku pÅ™cherza moczowego. <i>Nowotwory</i> , 2014, 64, 169-174.	0.1	0

#	ARTICLE	IF	CITATIONS
285	Clinical Scenario: Bladder Preservation. , 2015, , 379-386.		0
292	Alternative Verfahren bei Urothelkarzinom. , 2016, , 99-127.		0
293	Clinical Results for Bladder Cancer Treated by Radiotherapy Without Concurrent Standard Chemotherapy. Anticancer Research, 2016, 36, 5519-5526.	0.5	5
294	Radiation Therapy in Bladder Cancer. , 2018, , 1-12.		0
295	Multimodality Treatment for Bladder Conservation. , 2018, , 1-10.		0
296	Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Bladder Cancer. , 2018, , 743-754.		0
297	Radiotherapy for the Treatment of Muscle-Invasive Bladder Cancer. , 2018, , 83-89.		0
298	Genitourinary System Cancers. , 2019, , 269-307.		0
299	Trimodality Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer: Mansoura Experience. Cancer Research Journal, 2019, 7, 1.	0.0	3
300	Regional Therapy of Bladder Tumors. , 2020, , 413-425.		0
301	Comparison of Outcomes Between Radical Radiotherapy and Radical Cystectomy in Muscle Invasive Bladder Cancer in a Cancer Specialized Unit of a Developing Country. Cureus, 2020, 12, e10057.	0.2	1
302	Effect of internal iliac artery chemotherapy after transurethral resection of bladder tumor for muscle invasive bladder cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2014, 26, 558-63.	0.7	1
303	Repeated transurethral resection for non-muscle invasive bladder cancer. International Journal of Clinical and Experimental Medicine, 2015, 8, 1416-9.	1.3	7
304	Standard cystectomy fits all: truth or myth?. Translational Andrology and Urology, 2015, 4, 254-60.	0.6	10
305	Bladder Cancer Academy 2019 Selected Summaries. Reviews in Urology, 2019, 21, 23-28.	0.9	3
306	Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment. Clinical Advances in Hematology and Oncology, 2017, 15, 543-551.	0.3	6
307	Comparative Analysis between Radical Cystectomy and Trimodality Therapy for Clinical Stage II Bladder Cancer. Urological Science, 2018, 29, 25-32.	0.2	0
308	A Prospective Study of a Resorbable Intravesical Fiducial Marker for Bladder Cancer Radiation Therapy. Advances in Radiation Oncology, 2022, 7, 100858.	0.6	3

#	ARTICLE	IF	CITATIONS
309	The Effect of Tri-Modality Therapy with Bladder Preservation for Selective Muscle-Invasive Bladder Cancer. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110623.	0.8	1
310	Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent. <i>BJU International</i> , 2022, 130, 764-775.	1.3	3
313	Urothelkarzinom der Harnblase: Radiotherapeutische Verfahren. <i>Springer Reference Medizin</i> , 2022, , 1-5.	0.0	0
314	Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder. <i>Investigative and Clinical Urology</i> , 2022, 63, 168.	1.0	4
319	Clinical Trial Considerations for Bladder Preservation in Muscle-Invasive Bladder Cancer. <i>Advances in Oncology</i> , 2022, 2, 213-225.	0.1	0
320	Optimisation of Radiation Therapy in Bladder Preservation Therapy for Patients With Clinical Stage T2N0M0 Bladder Cancer. <i>Clinical Oncology</i> , 2022, , .	0.6	1
321	Prevalence and outcomes of transurethral resection versus radical cystectomy for muscle-infiltrating bladder cancer in the United States: A population-based cohort study. <i>International Journal of Surgery</i> , 2022, 103, 106693.	1.1	5
322	The efficacy of trimodal chemoradiotherapy with gemcitabine and cisplatin as a bladder-preserving strategy for the treatment of muscle-invasive bladder cancer: a single-arm phase II study. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	0
324	Impact of Programmed Death-ligand 1 Expression on Oncological Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Radiation-based Therapy. <i>European Urology Open Science</i> , 2022, 43, 14-21.	0.2	2
325	Guideline on trimodal therapy of bladder cancer (Nevskiy consensus 2021). <i>Onkourologiya</i> , 2022, 18, 142-163.	0.1	0
327	Glabridin inhibits urothelial bladder carcinoma cell growth <i>in vitro</i> and <i>in vivo</i> by inducing cell apoptosis and cell cycle arrest. <i>Chemical Biology and Drug Design</i> , 2023, 101, 581-592.	1.5	3
328	Optimized Adaptive Radiotherapy with Individualized Plan Library for Muscle-Invasive Bladder Cancer Using Internal Target Volume Generation. <i>Cancers</i> , 2022, 14, 4674.	1.7	6
329	Radical Transurethral Resection of Bladder Tumor in Organ-confined Muscle-invasive Bladder Cancer: Yes!. <i>European Urology Focus</i> , 2023, 9, 225-226.	1.6	1
330	Therapeutic Landscape Beyond Immunotherapy in Advanced Urothelial Carcinoma: Moving Past the Checkpoint. <i>Drugs</i> , 2022, 82, 1649-1662.	4.9	5
331	Adjuvant Radiotherapy for Upper Tract Urothelial Carcinoma: Systematic Review and Meta-Analysis. <i>Current Oncology</i> , 2023, 30, 19-36.	0.9	2
332	Comparative effectiveness of radiation versus radical cystectomy for localized muscle-invasive bladder cancer. <i>Advances in Radiation Oncology</i> , 2022, , 101157.	0.6	2
333	Elevated Baseline Neutrophil Count Correlates with Worse Outcomes in Patients with Muscle-Invasive Bladder Cancer Treated with Chemoradiation. <i>Cancers</i> , 2023, 15, 1886.	1.7	2
334	Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Chemoradiotherapy Versus Chemoradiotherapy Alone in Muscle-invasive Bladder Cancer: The MK-3475-992/KEYNOTE-992 Trial. <i>European Urology Focus</i> , 2023, 9, 227-228.	1.6	5

#	ARTICLE	IF	CITATIONS
335	Clinical outcomes of adapted hypofractionated radiotherapy for bladder cancer in elderly patients. BJU International, 0, , .	1.3	1
336	Combined Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer: How (Should) We Do It? A Narrative Review. Journal of Clinical Medicine, 2023, 12, 1560.	1.0	2
337	Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023. , 2023, 11, e006551.		8
338	Trimodal organâ€preserving treatment of muscleâ€invasive bladder cancer. IssledovaniÃ I Praktika V Medicine, 2023, 10, 111-125.	0.1	0
344	Urothelkarzinom der Harnblase: Radiotherapeutische Verfahren. Springer Reference Medizin, 2023, , 825-829.	0.0	0